BRCA2 and neoplasm: In addition, a-Egfl6 + a-PD-L1 combination therapy increased the number of CD8+ T cells in the 2F8c-Egfl6 tumor model (Figure 5G, left panel), whereas no difference in total number of CD8+ T cells or specific subpopulations, such as CD8+ Teff (CD44+CD62L–) was detected in the ID8p53–/– Brca2–/–-Egfl6 model (Figure 5G, right panel and Supplemental Figure 5B).